查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1715613

细胞治疗技术市场：按产品、治疗类型、製造流程、交付方式、应用、最终用户 - 2025-2030 年全球预测

Cell Therapy Technologies Market by Offering, Therapy Type, Manufacturing Process, Delivery Method, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计细胞治疗技术市场规模在 2024 年将达到 46.6 亿美元，在 2025 年将达到 52.9 亿美元，复合年增长率为 14.05%，到 2030 年将达到 102.5 亿美元。

主要市场统计数据
基准年2024年 46.6亿美元
预计2025年 52.9亿美元
预测年份 2030 102.5亿美元
复合年增长率（%） 14.05%

细胞治疗技术领域已迅速成为现代医学创新的基石，为再生医学和肿瘤学领域的突破性治疗提供了可能。市场正在见证突破性科学发现的涌入和投资的激增，这些正在重新定义传统治疗方法的局限性。随着行业相关人员应对日益复杂的法规环境并满足不断增长的患者期望，对可靠的市场洞察力的需求从未如此强烈。

实验室技术、製造流程和品管方法的最新进展为新型细胞治疗方法的商业化铺平了道路。在公共和私营部门投资的推动下，生态系统正以惊人的速度发展。本分析概述摘要了细胞治疗技术的创新精神，并深入检验了市场区隔、区域趋势和主要产业参与者等关键因素。以下讨论旨在为决策者提供对这一动态格局中的趋势、机会和挑战的平衡、基于事实的理解。

重塑细胞治疗格局的变革

近年来，科学创新、策略性投资和不断变化的监管环境的结合极大地改变了细胞​​治疗技术格局。生物加工和自动化领域的新兴技术彻底改变了製造业，提高了效率和扩充性。此外，数位化进步在将数据主导的洞察力与传统的实验室为基础的方法相结合方面发挥着关键作用，从而实现更精确的治疗并确保严格的品管。

跨学科合作也正在重塑市场动态，使学术机构和生物製药公司能够汇集资源和专业知识，快速开发突破性药物。该地区的监管机构正在实施前瞻性政策，不仅可以保护病人安全，还可以加快产品上市时间。除了这些渐进式的转变之外，消费者对个人化、微创治疗的需求也不断增长。这些因素共同表明，该行业正在从实验性治疗转向广泛可用、高效的治疗方案。技术创新、监管和市场需求的相互作用继续为创造性破坏和转型潜力提供条件。

细胞治疗技术市场的关键细分洞察

对市场的详细研究揭示了关键的细分维度，为了解细胞治疗技术的多样化分类提供了见解。根据产品分析，市场分为消耗品、设备、软体及服务，其中设备本身分为生物反应器和细胞分析仪，而软体及服务进一步分为资料管理和品管。这种层次细分突显了供应链的多面性以及数位解决方案与传统硬体的整合正在推动市场发展。

根据治疗方法类型进一步分类包括同种异体细胞疗法、自体细胞疗法和基因改造细胞疗法。具体分析来看，同种异体细胞治疗包括树突细胞、诱导性多功能干细胞、自然杀手细胞等，自体细胞治疗则包括造血干细胞、间质干细胞、T细胞等。基因改造细胞疗法进一步将市场细分为CAR-T细胞疗法和TCR疗法，突显了基因工程和个人化医疗之间的相互作用。

细胞培养可分为二维和三维培养系统，细胞生长分为贴壁培养和悬浮培养，细胞分离分为萤光激活细胞分选和磁激活细胞分选。基于递送方法的分析区分了体外和体内方法，而按应用细分则透过对心血管疾病、肌肉骨骼疾病、神经神经退化性疾病和肿瘤学等市场机会进行分类并提供进一步的子类别，从而提供了细緻的概述。最后，按最终用户细分包括生物製药公司、医院（进一步细分为私人和公共部门）、研究机构（包括政府研究中心和大学）。这些见解提供了製定策略以满足每个细分市场的特定需求的详细蓝图，从而确保有针对性的成长和最佳的资源配置。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 提高患者对个人化医疗解决方案的认识和接受度
      • 全球慢性病和遗传疾病的盛行率不断上升
      • 增加政府和私人对研发的资助
    • 限制因素
      • 细胞治疗技术高成本
    • 机会
      • 整合细胞疗法和药物创新，满足未满足的医疗需求
      • 扩大生技公司与医疗机构之间的合作，以创新细胞疗法
    • 任务
      • 临床试验中招募和留住病患的困难
  • 市场区隔分析
    • 治疗类型：增加自体细胞疗法的使用，以最大限度地降低免疫排斥的风险
    • 应用：细胞治疗技术在心血管疾病的应用日益增多，以促进血管生成和修復心肌组织。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章 细胞治疗技术市场：依产品

  • 耗材
  • 装置
    • 生物反应器
    • 细胞分析仪
  • 软体和服务
    • 资料管理
    • 品管

第七章 细胞治疗技术市场（依治疗类型）

  • 同种异体细胞治疗
    • 树突状细胞
    • 诱导多功能细胞
    • 自然杀手细胞
  • 自体细胞疗法
    • 造血干细胞
    • 间质干细胞
    • T细胞
  • 基因工程细胞疗法
    • CAR-T细胞疗法
    • TCR（T细胞受体）疗法

第八章细胞治疗技术市场：依製造工艺

  • 细胞培养
    • 二维培养系统
    • 3D培养系统
  • 细胞增殖
    • 持久的文化
    • 悬浮培养
  • 细胞分离
    • 萤光活化细胞分选
    • 磁激活细胞分选

第九章 细胞治疗技术市场：依交付方式

  • 体外
  • In vivo

第 10 章细胞治疗技术市场：按应用

  • 心血管疾病
    • 缺血性心臟疾病
    • 周边动脉疾病
  • 肌肉骨骼疾病
    • 骨关节炎
    • 类风湿性关节炎
  • 神经退化性疾病
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 血癌
    • 固态肿瘤
      • 乳癌
      • 肺癌
      • 摄护腺癌

第 11 章 细胞治疗技术市场（依最终使用者）

  • 生物製药公司
  • 医院
    • 私立医院
    • 公立医院
  • 研究组织
    • 政府研究中心
    • 大学学术

第 12 章：美洲细胞治疗技术市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第 13 章：亚太细胞治疗技术市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 14 章欧洲、中东和非洲细胞治疗技术市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Adaptimmune Limited
  • Allogene Therapeutics Inc.
  • Atara Biotherapeutics, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bluebird Bio Inc.
  • Cellectis SA
  • Century Therapeutics, Inc.
  • Charles River Laboratories International, Inc.
  • ElevateBio LLC
  • Gamida Cell Ltd.
  • GE HealthCare Technologies Inc.
  • Gilead Sciences, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Legend Biotech USA Inc.
  • Novartis AG
  • Sartorius AG
  • STEMCELL Technologies Inc.
  • Takara Bio Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vericel Corporation
Product Code: MRR-034230D3E636

The Cell Therapy Technologies Market was valued at USD 4.66 billion in 2024 and is projected to grow to USD 5.29 billion in 2025, with a CAGR of 14.05%, reaching USD 10.25 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.66 billion
Estimated Year [2025] USD 5.29 billion
Forecast Year [2030] USD 10.25 billion
CAGR (%) 14.05%

The field of cell therapy technologies has rapidly emerged as a cornerstone of modern medical innovation, enabling transformative treatments in regenerative medicine and oncology. This market is witnessing an influx of groundbreaking scientific discoveries and a surge in investments that are redefining the boundaries of traditional therapeutic approaches. As industry stakeholders navigate increasingly complex regulatory environments and manage escalating patient expectations, the need for robust market insights has never been greater.

Recent advancements in laboratory techniques, manufacturing processes, and quality control methodologies have paved the way for the commercialization of novel cell-based treatments. Driven by both public and private sector investments, the ecosystem is evolving at a breakneck pace. This analytical overview encapsulates the innovative spirit of cell therapy technologies while providing a detailed examination of pivotal factors such as market segmentation, geographic trends, and leading industry players. The discussion that follows is designed to furnish decision-makers with a balanced, fact-based understanding of trends, opportunities, and challenges in this dynamic landscape.

Transformative Shifts Reshaping the Cell Therapy Technologies Landscape

In recent years, transformative shifts have redefined the cell therapy technologies landscape, driven by a confluence of scientific innovation, strategic investment, and evolving regulatory frameworks. Emerging technologies in bioprocessing and automation have revolutionized manufacturing, leading to improved efficiency and scalability. In addition, digital advancements are now playing a critical role in integrating data-driven insights with traditional lab-based approaches, thereby enabling more precise therapies and ensuring rigorous quality control.

Market dynamics are also reshaped by cross-disciplinary collaborations, with academic institutions and biopharmaceutical companies pooling resources and expertise to fast-track breakthroughs. Regulatory agencies across various regions have introduced forward-thinking policies that not only safeguard patient safety but also promote accelerated pathways to market. These progressive shifts are complemented by a growing consumer demand for therapies that are personalized and minimally invasive. Together, these factors signal an industry transitioning from experimental treatments to widely accessible, highly effective therapeutic solutions. The interplay between innovation, regulation, and market demand continues to sculpt the landscape, providing an environment ripe for disruptive growth and transformative potential.

Key Segmentation Insights in the Cell Therapy Technologies Market

An in-depth exploration of the market reveals critical segmentation dimensions that provide insights into the diverse categorizations within cell therapy technologies. When analyzed based on offering, the market is categorized into consumables, equipment, and software and services, where equipment itself is divided into bioreactors and cell analyzers, and software and services further bifurcate into data management and quality control. This layered segmentation underscores the multifaceted nature of supply chains and the integration of digital solutions with traditional hardware in driving market advancement.

Further segmentation by therapy type distinguishes between allogeneic cell therapy, autologous cell therapy, and gene-modified cell therapy. Detailed analysis shows that allogeneic cell therapy branches out into dendritic cells, induced pluripotent stem cells, and natural killer cells, while autologous cell therapy covers hematopoietic stem cells, mesenchymal stem cells, and T-cells. Gene-modified cell therapy refines the market further into CAR-T cell therapy and TCR therapy, highlighting the interplay between genetic engineering and personalized medicine.

Additional segmentation is observed in the manufacturing process, where distinctions are made across cell culture, cell expansion, and cell separation; cell culture is split into 2D and 3D culture systems, cell expansion into adherent and suspension cultures, and cell separation into fluorescence-activated cell sorting and magnetic-activated cell sorting. Analysis based on delivery method differentiates between ex vivo and in vivo approaches, and segmentation by application categorizes market opportunities in cardiovascular disease, musculoskeletal disorders, neurodegenerative diseases, and oncology, with further sub-categories providing a nuanced overview. Finally, segmentation by end user encompasses biopharmaceutical companies, hospitals - further analyzed into private and public segments - and research institutes, which include government research centers and universities. These insights offer a detailed roadmap for tailoring strategies that cater to the specific needs of each segment, thus ensuring targeted growth and optimized resource allocation.

Based on Offering, market is studied across Consumables, Equipment, and Software & Services. The Equipment is further studied across Bioreactors and Cell Analyzers. The Software & Services is further studied across Data Management and Quality Control.

Based on Therapy Type, market is studied across Allogeneic Cell Therapy, Autologous Cell Therapy, and Gene-Modified Cell Therapy. The Allogeneic Cell Therapy is further studied across Dendritic Cells, Induced Pluripotent Stem Cells, and Natural Killer Cells. The Autologous Cell Therapy is further studied across Hematopoietic Stem Cells, Mesenchymal Stem Cells, and T-Cells. The Gene-Modified Cell Therapy is further studied across CAR-T Cell Therapy and TCR (T-Cell Receptor) Therapy.

Based on Manufacturing Process, market is studied across Cell Culture, Cell Expansion, and Cell Separation. The Cell Culture is further studied across 2D Culture Systems and 3D Culture Systems. The Cell Expansion is further studied across Adherent Culture and Suspension Culture. The Cell Separation is further studied across Fluorescence-Activated Cell Sorting and Magnetic-Activated Cell Sorting.

Based on Delivery Method, market is studied across Ex vivo and In vivo.

Based on Application, market is studied across Cardiovascular Disease, Musculoskeletal Disorders, Neurodegenerative Diseases, and Oncology. The Cardiovascular Disease is further studied across Ischemic Heart Disease and Peripheral Artery Disease. The Musculoskeletal Disorders is further studied across Osteoarthritis and Rheumatoid Arthritis. The Neurodegenerative Diseases is further studied across Alzheimer's Disease and Parkinson's Disease. The Oncology is further studied across Hematological Cancer and Solid Tumors. The Solid Tumors is further studied across Breast Cancer, Lung Cancer, and Prostate Cancer.

Based on End User, market is studied across Biopharmaceutical Companies, Hospitals, and Research Institutes. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Research Institutes is further studied across Government Research Centers and University Academics.

Key Regional Trends Driving Global Market Dynamics

The global cell therapy technologies market is experiencing region-specific trends that highlight diverse adoption patterns and investment priorities. In the Americas, there is a robust focus on capitalizing on fast-paced innovation alongside a well-established regulatory framework that supports rapid market entry and commercialization. Europe, the Middle East & Africa exhibit a blend of regulatory stringency and emerging market opportunities, with research and healthcare institutions driving early-stage clinical developments and technology integration. Meanwhile, the Asia-Pacific region has emerged as a fertile ground for scaling innovations, offering extensive support for research collaborations and a surge in infrastructure investments that facilitate local manufacturing and quality control advancements.

These regional insights reflect varied yet interconnected approaches to implementing cell therapy solutions across different healthcare ecosystems. By recognizing the strategic strengths of each region, stakeholders can better align their investment and operational strategies to tap into localized opportunities while balancing broader global trends. Careful consideration of these geographical factors is essential for optimizing market entry strategies and ensuring sustainable long-term growth.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Companies Shaping the Future of Cell Therapy Technologies

Several key players have emerged as frontrunners in the cell therapy technologies space, driving innovations that are reshaping the therapeutic landscape. Companies such as Adaptimmune Limited, Allogene Therapeutics Inc., and Atara Biotherapeutics, Inc. are at the forefront of developing pioneering treatments, leveraging advancements in cellular engineering and process optimization. Notably, Bellicum Pharmaceuticals, Inc. and Bluebird Bio Inc. have carved a niche with their focus on next-generation immunotherapies, while Cellectis SA and Century Therapeutics, Inc. are redefining manufacturing techniques to ensure scalability and clinical efficacy.

Other leading companies, including Charles River Laboratories International, Inc., ElevateBio LLC, and Gamida Cell Ltd., have been instrumental in providing comprehensive R&D and manufacturing support, thus facilitating innovative breakthroughs across the board. The integrated contributions of GE HealthCare Technologies Inc., Gilead Sciences, Inc., and Iovance Biotherapeutics, Inc. further highlight an established commitment to improving patient outcomes through state-of-the-art technologies. Moreover, industry giants such as Johnson & Johnson Services, Inc. and Legend Biotech USA Inc. continue to invest in clinical trials and strategic partnerships, while Novartis AG, Sartorius AG, and STEMCELL Technologies Inc. drive operational excellence through rigorous process improvements. The impactful endeavors of Takara Bio Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vericel Corporation collectively illustrate the sector's momentum toward transformative therapeutic solutions.

The report delves into recent significant developments in the Cell Therapy Technologies Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Limited, Allogene Therapeutics Inc., Atara Biotherapeutics, Inc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Cellectis SA, Century Therapeutics, Inc., Charles River Laboratories International, Inc., ElevateBio LLC, Gamida Cell Ltd., GE HealthCare Technologies Inc., Gilead Sciences, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., Legend Biotech USA Inc., Novartis AG, Sartorius AG, STEMCELL Technologies Inc., Takara Bio Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vericel Corporation. Actionable Recommendations for Industry Leaders in Cell Therapy Technologies

For decision-makers and strategists poised to capitalize on the evolving opportunities in the cell therapy technologies market, several actionable recommendations stand out. Firstly, leaders should prioritize investment in research and development initiatives that emphasize scalability and process optimization, ensuring that emerging trends in manufacturing and digital integration are fully leveraged. Embracing collaborative models that incorporate partnerships between technological innovators, therapeutic developers, and clinical researchers can further expedite product development and market entry.

It is also imperative to enhance regulatory compliance frameworks by staying current with evolving global standards, particularly those concerning quality control and data integrity. By instituting rigorous internal protocols and adopting state-of-the-art process monitoring systems, companies can mitigate risks and maintain competitive advantages in a rapidly evolving environment. Additionally, fostering strong regional partnerships is crucial; tailoring strategies to market-specific needs in areas such as the Americas, Europe, Middle East & Africa, and Asia-Pacific will drive targeted growth and better resource allocation.

Finally, building robust portfolios that align product offerings across consumables, equipment, and integrated software and services can help maximize value across end user populations. Industry leaders should consistently re-evaluate market segmentation insights to identify emerging niche opportunities and adjust investment priorities accordingly. A proactive, multi-dimensional approach is essential for harnessing the full potential of this transformative market.

Conclusion: Charting the Course for Future Innovation in Cell Therapy Technologies

In summary, the multifaceted nature of the cell therapy technologies market presents both unprecedented opportunities and complex challenges. From a comprehensive review of segmentation facets-including offerings, therapy types, manufacturing processes, delivery methods, and end-user applications-to a detailed examination of regional trends and key industry players, it is evident that the market is poised for significant transformation. By synthesizing insights drawn from diverse dimensions of technological innovation, regulatory evolution, and market dynamics, stakeholders can develop tailored strategies that capture incremental value and drive long-term growth.

As the industry continues to evolve, it is crucial for companies to remain agile and responsive to emerging trends, ensuring that their innovation pipelines and operational strategies are in sync with the rapidly changing landscape. The insights presented in this analysis provide a clear roadmap for navigating the complex interplay of challenges and opportunities, ultimately laying the foundation for a future characterized by enhanced therapeutic impact and improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and acceptance among patients regarding personalized medicine solutions
      • 5.1.1.2. Increasing prevalence of chronic and genetic disorders worldwide
      • 5.1.1.3. Rising government and private funding support for research and development initiatives
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with cell therapy technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating cell therapies with pharmaceutical innovations to address unmet medical needs
      • 5.1.3.2. Growing partnerships between biotech companies and healthcare institutions for cell therapy innovations
    • 5.1.4. Challenges
      • 5.1.4.1. Difficulty in recruiting and retaining patients for clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Rising utilization of autologous cell therapy to minimize the risk of immune rejection
    • 5.2.2. Application: Rising application of cell therapy technologies in cardiovascular diseases to enhance angiogenesis and repair myocardial tissue
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell Therapy Technologies Market, by Offering

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Equipment
    • 6.3.1. Bioreactors
    • 6.3.2. Cell Analyzers
  • 6.4. Software & Services
    • 6.4.1. Data Management
    • 6.4.2. Quality Control

7. Cell Therapy Technologies Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Allogeneic Cell Therapy
    • 7.2.1. Dendritic Cells
    • 7.2.2. Induced Pluripotent Stem Cells
    • 7.2.3. Natural Killer Cells
  • 7.3. Autologous Cell Therapy
    • 7.3.1. Hematopoietic Stem Cells
    • 7.3.2. Mesenchymal Stem Cells
    • 7.3.3. T-Cells
  • 7.4. Gene-Modified Cell Therapy
    • 7.4.1. CAR-T Cell Therapy
    • 7.4.2. TCR (T-Cell Receptor) Therapy

8. Cell Therapy Technologies Market, by Manufacturing Process

  • 8.1. Introduction
  • 8.2. Cell Culture
    • 8.2.1. 2D Culture Systems
    • 8.2.2. 3D Culture Systems
  • 8.3. Cell Expansion
    • 8.3.1. Adherent Culture
    • 8.3.2. Suspension Culture
  • 8.4. Cell Separation
    • 8.4.1. Fluorescence-Activated Cell Sorting
    • 8.4.2. Magnetic-Activated Cell Sorting

9. Cell Therapy Technologies Market, by Delivery Method

  • 9.1. Introduction
  • 9.2. Ex vivo
  • 9.3. In vivo

10. Cell Therapy Technologies Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular Disease
    • 10.2.1. Ischemic Heart Disease
    • 10.2.2. Peripheral Artery Disease
  • 10.3. Musculoskeletal Disorders
    • 10.3.1. Osteoarthritis
    • 10.3.2. Rheumatoid Arthritis
  • 10.4. Neurodegenerative Diseases
    • 10.4.1. Alzheimer's Disease
    • 10.4.2. Parkinson's Disease
  • 10.5. Oncology
    • 10.5.1. Hematological Cancer
    • 10.5.2. Solid Tumors
      • 10.5.2.1. Breast Cancer
      • 10.5.2.2. Lung Cancer
      • 10.5.2.3. Prostate Cancer

11. Cell Therapy Technologies Market, by End User

  • 11.1. Introduction
  • 11.2. Biopharmaceutical Companies
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals
  • 11.4. Research Institutes
    • 11.4.1. Government Research Centers
    • 11.4.2. University Academics

12. Americas Cell Therapy Technologies Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Cell Therapy Technologies Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Cell Therapy Technologies Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Evotec and Novo Nordisk collaborate to advance off-the-shelf cell therapies
    • 15.3.2. CPC launches Aseptic Connector for enhanced cell and gene therapy cryopreservation
    • 15.3.3. Cellular Origins acquires Actia Platform IP to boost automated cell therapy manufacturing
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adaptimmune Limited
  • 2. Allogene Therapeutics Inc.
  • 3. Atara Biotherapeutics, Inc.
  • 4. Bellicum Pharmaceuticals, Inc.
  • 5. Bluebird Bio Inc.
  • 6. Cellectis SA
  • 7. Century Therapeutics, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. ElevateBio LLC
  • 10. Gamida Cell Ltd.
  • 11. GE HealthCare Technologies Inc.
  • 12. Gilead Sciences, Inc.
  • 13. Iovance Biotherapeutics, Inc.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Legend Biotech USA Inc.
  • 16. Novartis AG
  • 17. Sartorius AG
  • 18. STEMCELL Technologies Inc.
  • 19. Takara Bio Inc.
  • 20. Takeda Pharmaceutical Company Limited
  • 21. Thermo Fisher Scientific Inc.
  • 22. Vericel Corporation

LIST OF FIGURES

  • FIGURE 1. CELL THERAPY TECHNOLOGIES MARKET MULTI-CURRENCY
  • FIGURE 2. CELL THERAPY TECHNOLOGIES MARKET MULTI-LANGUAGE
  • FIGURE 3. CELL THERAPY TECHNOLOGIES MARKET RESEARCH PROCESS
  • FIGURE 4. CELL THERAPY TECHNOLOGIES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. CELL THERAPY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. CELL THERAPY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL THERAPY TECHNOLOGIES MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DATA MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NATURAL KILLER CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOPOIETIC STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY T-CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY TCR (T-CELL RECEPTOR) THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 2D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY 3D CULTURE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ADHERENT CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SUSPENSION CULTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY FLUORESCENCE-ACTIVATED CELL SORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MAGNETIC-ACTIVATED CELL SORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ISCHEMIC HEART DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 61. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 62. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HEMATOLOGICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 63. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 64. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 65. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 66. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 67. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 68. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 71. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 72. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 73. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 74. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 75. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 76. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 77. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY UNIVERSITY ACADEMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 78. GLOBAL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 79. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 80. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 81. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 82. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 87. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 88. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 89. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 90. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 94. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 95. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 97. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 99. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 100. AMERICAS CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 102. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 103. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 104. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 109. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 110. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 111. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 112. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 115. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 116. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 117. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 119. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 121. ARGENTINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 122. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 123. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 124. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 130. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 131. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 132. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 133. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 136. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 137. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 138. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 140. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 142. BRAZIL CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 143. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 144. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 145. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 146. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 149. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 151. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 152. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 153. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 154. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 155. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 158. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 159. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 161. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 163. CANADA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 164. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 165. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 166. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 167. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 172. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 173. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 174. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 175. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 178. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 179. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 180. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 182. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 184. MEXICO CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 201. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 202. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 203. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 205. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 206. UNITED STATES CELL THERAPY TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC CELL THERAPY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 229. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 230. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 234. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 237. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 238. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 239. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 240. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 241. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 243. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 245. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 247. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 249. AUSTRALIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 250. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 251. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 252. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 253. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 255. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 258. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 259. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 260. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 261. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 262. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 264. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 268. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 270. CHINA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 271. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 272. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 273. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 274. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 279. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 280. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 281. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 282. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 283. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 285. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 287. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 289. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 290. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 291. INDIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 292. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 293. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 294. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 295. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ALLOGENEIC CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY AUTOLOGOUS CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY GENE-MODIFIED CELL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 300. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL CULTURE, 2018-2030 (USD MILLION)
  • TABLE 301. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL EXPANSION, 2018-2030 (USD MILLION)
  • TABLE 302. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CELL SEPARATION, 2018-2030 (USD MILLION)
  • TABLE 303. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 304. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 305. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, 2018-2030 (USD MILLION)
  • TABLE 306. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 307. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY NEURODEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
  • TABLE 308. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
  • TABLE 310. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 312. INDONESIA CELL THERAPY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 313. JAPAN CELL THERAPY TECHNOLOGIES MARKET SIZE, BY OFFERING, 2018-2030 (USD